Phaseline

Companies › Advenchen Laboratories Nanjing

Advenchen Laboratories Nanjing: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 3, 1 Phase 1; Oncology; next expected readout Jul 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AL8326–Phase 3Small Cell Lung CarcinomaJul 2028
AL58805–Phase 1Advanced Tumors–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07179081AL58805Phase 1Advanced TumorsOncologyJan 2026
NCT06247605AL8326Phase 3Small Cell Lung CarcinomaOncologyJul 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Advenchen Laboratories OSE Immunotherapeutics Clarity Pharmaceuticals TYK Medicines Impact Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.